Global Chemotherapy Induced Peripheral Neuropathy Treatment Market and Forecast 2020-2026

                                          
CIPN is a common adverse effect of several cancer therapies including taxanes and platinum drugs. Symptoms include decreased sensation and tingling of the hands and feet, severe pain, numbness and muscle weakness, all of which can occur during cancer treatment, and frequently persist after chemotherapy has ended.

There are no approved therapies to combat the debilitating symptoms of CIPN now. Current alternatives include Palliative care using antidepressants, antiepileptic drugs, or opioids, all of which have well known adverse side effects.

By region, the United States has the highest share of income, reaching 47.25 percent in 2019.

Market Analysis and Insights: Global Chemotherapy Induced Peripheral Neuropathy Treatment Market
The research report studies the Chemotherapy Induced Peripheral Neuropathy Treatment market using different methodologies and analyzes to provide accurate and in-depth information about the market. For a clearer understanding, it is divided into several parts to cover different aspects of the market. Each area is then elaborated to help the reader comprehend the growth potential of each region and its contribution to the global market. The researchers have used primary and secondary methodologies to collate the information in the report. They have also used the same data to generate the current market scenario. This report is aimed at guiding people towards an apprehensive, better, and clearer knowledge of the market.

The global Chemotherapy Induced Peripheral Neuropathy Treatment market size is projected to reach US$ 2276.6 million by 2026, from US$ 1572.6 million in 2020, at a CAGR of 6.4% during 2021-2026.
Global Chemotherapy Induced Peripheral Neuropathy Treatment Scope and Segment

The global Chemotherapy Induced Peripheral Neuropathy Treatment market is segmented by company, region (country), by Type, and by Application. Players, stakeholders, and other participants in the global Chemotherapy Induced Peripheral Neuropathy Treatment market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by region (country), by Type, and by

Application for the period 2015-2026.

by Type, the market is primarily split into


 	
Calcium Channel Alpha2-delta Ligands
 	
Antidepressants
 	
Opioids
 	
Others

by Application, this report covers the following segments

 	
Platinum Agents
 	
Taxanes
 	
Vinca Alkaloids
 	
Others

The report lists the major players in the regions and their respective market share on the basis of global revenue. It also explains their strategic moves in the past few years, investments in product innovation, and changes in leadership to stay ahead in the competition. This will give the reader an edge over others as a well-informed decision can be made looking at the holistic picture of the market.

The Chemotherapy Induced Peripheral Neuropathy Treatment key players in this market include:

 	
Aptinyx Inc
 	
Asahi Kasei Pharma Corp
 	
Regenacy Pharmaceuticals
 	
MAKScientific LLC
 	
Metys Pharmaceuticals AG
 	
Nemus Bioscience Inc
 	
PledPharma
 	
Sova Pharmaceuticals Inc
 	
DermaXon LLC
 	
Kineta Inc
 	
Krenitsky Pharmaceuticals Inc
 	
PeriphaGen
 	
Apexian Pharma
 	
WinSanTor
 	
Solasia Pharma K.K.